Clinical Trial Update: Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating weekly docetaxel plus cisplatin as first-line therapy for nasopharyngeal carcinoma. The status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Samsung Medical Center | Conditions: Nasopharyngeal Cancer | Phase 2 | Status: UNKNOWN